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The safety and pharmacokinetics of rimantadine administered by small-particle aerosol were assessed in
healthy adults and adults with acute influenza virus infection. Aerosolized rimantadine delivered at a
concentration of 40 ,Ig/liter of air was associated with nasal burning and irritation in normal volunteers. A
concentration of 20 ,ug/liter of air was well tolerated for up to 12 h by normal volunteers and was not associated
with any changes in pulmonary function, as measured by routine spirometry, plethysmography, or diffusion
capacity of carbon monoxide. Mean peak levels of drug in serum were approximately 10-fold lower after 12 h
of aerosol administration than they were after oral administration of 200 mg (29.7 versus 255 ng/ml,
respectively), while mean nasal wash levels were approximately 100-fold higher (6,650 versus 66.6 ng/ml,
respectively). Elimination half-lives were similar after both aerosol and oral administration (24.1 and 25.2 h,
respectively), and rimantadine urinary excretion was <1% per 24 h in both groups. Twenty micrograms of
aerosolized rimantadine per liter of air given 12 h daily for 3 days to nine adults with acute influenza virus
infection was well tolerated. Levels in plasma after 12 h of aerosol inhalation were similar to those in normal
volunteers, but were higher at the end of the third treatment than they were at the end of the first treatment
(88.3 versus 47.9 ng/ml, respectively). Thus, rimantadine delivered via small-particle aerosol at a dose of 20
jig/liter of air was well tolerated in normal volunteers and in those with acute influenza and was associated with
high local concentrations.
Small-particle aerosol (SPA) delivery of antiviral agents
was evaluated for the treatment of viral respiratory tract
infections. This method of drug administration usually re-
sults in higher concentrations of drug at the site of infection
than systemic administration does, may decrease or amelio-
rate systemic toxicities seen after systemic administration,
and has been more effective than the systemic administration
of antiviral agents in murine (31) and ferret (9) animal models
of acute influenza virus infection. SPA delivery of antiviral
agents has also been effective in the treatment of human
respiratory viral diseases (13, 14, 17, 22, 24, 28).
Rimantadine has better antiviral activity against some
influenza A virus strains than amantadine does (5), is better
tolerated when taken orally (8), and is effective as a prophy-
lactic (8, 35) and therapeutic (20, 26, 30, 34, 35) agent in
influenza A virus infections. Hayden et al. (22) have previ-
ously reported the use of rimantadine delivered by ultrasonic
nebulizer in subjects given an attenuated influenza A virus;
except for minor complaints, the drug was well tolerated. No
pharmacokinetic data were reported.
Although the combination of amantadine or rimantadine
with ribavirin has been shown to have additive or synergistic
activity in vitro (6, 21) and when administered systemically
in a murine model of acute influenzal pneumonia (11, 33),
only the combination of ribavirin and amantadine adminis-
tered via SPA has been examined in an animal (murine)
model and has been found to be more effective than single-
agent therapy (33). Similar studies have not yet been done in
humans. Because of its greater activity in vitro, rimantadine
would be a logical choice for study in combination with
ribavirin in humans. However, before the evaluation of SPA
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delivery of combined ribavirin and rimantadine therapy for
acute influenza can be tested, the safety of rimantadine SPA
delivery needs further evaluation. The purpose of this study
was to evaluate the safety, tolerability, and pharmacokinet-
ics of rimantadine when delivered by SPA.
(Preliminary data from this study were presented at the
28th Interscience Conference on Antimicrobial Agents and
Chemotherapy [R. L. Atmar, S. B. Greenberg, J. Quarles, S.
Wilson, B. Tyler, and R. B. Couch, Program Abstr. 28th
Intersci. Conf. Antimicrob. Agents Chemother., abstr. no.
95, 1988].)
MATERIALS AND METHODS
SPA delivery of rimantadine. The SPA was generated from
a continuous-flow, modified Collison nebulizer of the Fort
Detrick design which has been described in detail previously
(23). Sterile water was used as the placebo aerosol. For most
studies, rimantadine was dissolved in sterile water at con-
centrations of 4 or 2 mg/ml; aerosols of 40 or 20 ,ug of
rimantadine per liter of air, respectively, were generated
from these reservoirs. In one group of volunteers, the
rimantadine was dissolved in phosphate-buffered saline
(PBS). The aerosol was delivered to the volunteers via
Puritan Benefit masks at 12.5 liter/min. The masks covered
each volunteer's mouth and nose. A delivered dose was
calculated by using a quadratic equation for tidal volume and
by estimating a 70% retention rate (25). The distribution of
deposition of an aerosol generated from this nebulizer was
determined previously; approximately 62% of the delivered
dose would be deposited in the nasopharynx, 18% would be
deposited in the tracheobronchial tree, and 20% would be
deposited in the alveoli (25).
Safety evaluation in normal healthy adults. Twenty-one
normal, healthy volunteers (ages, 22 to 31 years) participated
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in the first part of the study, after giving written informed
consent. Before enrollment, history, physical examination,
and pulmonary function testing were performed. Female
volunteers had negative serum pregnancy tests. No volun-
teer gave a history of asthma, lung disease, or other chronic
disease.
All subjects were blinded and assigned to receive placebo
or rimantadine SPA. They were subsequently crossed over
to receive the other SPA (usually on the following day).
Before and after each aerosol exposure, volunteers were
questioned and examined for possible side effects by a
nonblinded observer (R.L.A.). Symptom scores were calcu-
lated as the presence of a symptom (score of 1) multiplied by
severity (mild = 1, moderate = 2, severe = 3, stopped
inhalation = 4). The respiratory symptoms that were evalu-
ated included sneezing, nasal obstruction, nasal discharge,
nasal irritation, and sore throat. Nonrespiratory symptoms
included tearing, dysgeusia, dizziness, sleepiness, headache,
difficulty concentrating, and anxiety.
Two volunteers underwent 15-min exposures to aerosol at
a rimantadine (in sterile water) concentration of 40,ug/liter of
air, two others had 60-min exposures, two had 120-min
exposures, and four had 4-h exposures. Four volunteers
underwent 4-h exposures to SPA generated at a rimantadine
(in PBS) concentration of 40 ,ug/liter of air. Because of
significant local (nasal) side effects, the rimantadine aerosol
concentration was decreased to 20 jig/liter of air, and four
volunteers then inhaled aerosol for 4 h, four volunteers
inhaled aerosol for 8 h, and five volunteers inhaled aerosol
for 12 h.
For the five volunteers who received 12-h inhalations,
pharmacokinetic studies were performed in the General
Clinical Research Center at The Methodist Hospital. Plasma
samples were obtained at 0, 2, 4, 6, 12, 18, 24, 48, and 72 h
after the beginning of aerosol exposure. By using 5 ml of
Ringer lactate solution per nostril, nasal wash specimens
were obtained for determination of drug levels at 0 and 12 h.
Twenty-four-hour urine collections (beginning at the initia-
tion of aerosol exposures) were obtained for determination
of drug excretion. All procedures were repeated several
weeks later, when these five subjects were rehospitalized
and given a 200-mg oral dose of rimantadine.
Pulmonary function testing was begun within 30 min after
completion of 4-, 8-, and 12-h aerosol exposures. Routine
spirometry was performed on a Medical Graphics pneumo-
tachymeter; and forced expiratory volume (FEV1), forced
vital capacity (FVC), FEV1/FVC, and forced expiratory flow
25 to 75% (FEF2575) were measured. Spirometry and data
collection were performed in accordance with the criteria
outlined previously (2). Lung volumes and airway resistance
were determined by the shallow panting technique on a
Medical Graphics body plethysmograph. Single-breath dif-
fusing capacity of carbon monoxide was determined with a
PK Morgan Analyzer by using 9.70% helium, 0.294% CO,
and 20.6% 02 as a test gas.
Evaluation in volunteers with a febrile upper respiratory
infection. Eighteen volunteers (ages, 18 to 24 years) partici-
pated in the evaluation of febrile upper respiratory infection
after giving written informed consent. At the time of enroll-
ment, all had symptoms and signs of acute, febrile (>38.3°C)
upper respiratory viral infection (nasal congestion, sore
throat) with a duration of less than 24 h; influenza A virus
subtype H3N2 was subsequently isolated from 13 volunteers
and influenza B virus was isolated from 5 volunteers by
previously described methods (3). For each volunteer, base-
line history, physical examination, complete blood count,
blood chemistries, bacterial throat culture, and urinalysis
were obtained. The complete blood count and chemistries
were repeated at the time of discharge and at 1 and 4 weeks
after enrollment. Female volunteers had a negative urine
pregnancy test before enrollment. No volunteer gave a
history of asthma, chronic lung disease, or other chronic
disease.
After enrollment, all subjects were hospitalized for 3 days
in the Beutel Health Center on the Texas A&M University
campus and were blinded and randomized to receive placebo
or rimantadine SPA. Volunteers inhaled aerosol (20 p,g/liter
of air) for 12 h on the day of enrollment and then for 12 h on
a set schedule between 0730 and 2130 hours for the following
2 days. After discharge, they were seen at follow-up 1 and 4
weeks later.
The first six volunteers were evaluated for signs of toxicity
by a nonblinded observer (R.L.A.) every 15 min during the
first hour of SPA exposure and hourly thereafter. On the
next 2 days they were examined every 2 h. The remaining 12
volunteers were evaluated for toxicity at 15 min and 1, 2, 4,
8, and 12 h on the first day and intermittently on the
following days. Each volunteer was examined twice daily
during the hospitalization by a blinded observer (B.T.) to
assess his or her clinical status, and nonblinded evaluations
(R.L.A.) were performed at the 1- and 4-week follow-up
visits.
Plasma for drug level determinations was obtained at 0, 2,
4, 8, and 12 h during the first SPA exposure. Drug levels in
plasma were also obtained at the end of treatment, on the
last day of SPA exposure, and on the following morning
prior to discharge. Nasal washes and urine collections for
drug levels were not done in this group of volunteers.
Environmental sampling. Environmental (room air) sam-
pling for rimantadine levels was done while the first two ill
volunteers were receiving therapy. Paired 5-min collections
with all glass impingers were collected in 20 ml of sterile
water at 15 min and 2, 4, 8, and 12 h on the first day and at
0, 2,4, 8, and 12 h on the following 2 days. Two investigators
kept logs of the time spent in the volunteers' rooms, and
drug levels in plasma were measured daily at the end of each
day's aerosol inhalation. Thereafter, drug levels in plasma
were determined in one investigator weekly for 2 weeks.
Drug levels. Plasma, urine, and nasal wash specimens
were assayed for rimantadine by gas chromatography plus
mass spectrometry (TexMS Analytical Services, Houston,
Tex.) by previously described methods (10). Deuterated
rimantadine served as an internal standard. The ratio of peak
heights and concentrations of known calibration standards
were used to generate a standard curve by using weighted
(1/y2), nonlinear regression; drug concentration of unknown
samples could be calculated from these ratios. Drug concen-
trations were assayed over a range of 5 to 500 ng/ml. The
interassay variability for plasma levels was 1.2% relative
standard deviation, and the intraassay variability was 4.5%
relative standard deviation.
Pharmacokinetic analysis. The elimination rate constant
(kel) was calculated from the slope of the log-linear portion of
the decay of the rimantadine plasma concentration-versus-
time curve. All slopes were calculated by linear regression of
the natural logarithm of concentration against time. The area
under the curve from initiation of the dose (time zero) to
infinity (AUC,_) was calculated by the LaGrange method
by using the LAGRAN computer program (27). From kei and
AUC_, the following parameters were calculated for
rimantadine disposition for each subject: elimination half-life
= 0.693/kel; total plasma clearance (CL) = F. dose/AUCO ,
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TABLE 1. Symptom scores associated with rimantadine SPA
inhalation in normal volunteers
Aerosol group Symptom score (mean)"
(concn) Respiratory Nonrespiratory Total
Rimantadine in H20 30c,d 0.7 3.7e
(40 pg/liter of air)b
Placebob 0.5c 0.7 1.2e
Rimantadine in PBS 3.9e 1.0 4.9
(40 ,g/liter of air)f
Placebof 0.8e 1.5 2.3
Rimantadine in H20 1.5 0.3 1.9
(20 ,g/liter of air)9
Placebog 0.9 0.5 1.4
a Symptom scores were calculated as the presence of the symptom (score of
1) multiplied by its severity (mild, 1; moderate, 2; severe, 3; stopped
inhalation, 4). Respiratory symptoms included sneezing, nasal obstruction,
nasal discharge, nasal irritation, and sore throat. Nonrespiratory symptoms
included tearing, dysgeusia, dizziness, sleepiness, headache, difficulty con-
centrating, and anxiety.
b Duration of inhalation was 15 min to 4 h; placebo was sterile water (n =
10).
' P < 0.01 for rimantadine versus placebo by the Wilcoxon rank sum test.
d Nasal irritation was the only symptom that occurred significantly more
often in the rimantadine group than in the placebo group (9 of 10 versus 0 of
10 volunteers, respectively; P = 0.0001 by the Fisher two-tailed exact test).
e p < 0.05 for rimantidine versus placebo by the Wilcoxon rank sum test.
f Duration of inhalation was 4 h; placebo was sterile water (n = 4).
g Duration of inhalation was 4 to 12 h; placebo was sterile water (n = 13).
where F represents the fraction of drug reaching the
systemic circulation; and volume of distribution (V) = F-
CL/kel. The bioavailability of the aerosol dose compared
with that after oral administration was calculated from
the relationship: bioavailabilityspA,Oral (F) = AUC0_ SPA/
AUCo,,Oral. These values were corrected for dose and
half-life differences (12). Peak drug levels were considered to
be the highest levels measured.
Statistical methods. Unpaired and paired Student's t tests,
chi-square with the Yates correction, the Fisher two-tailed
exact test, and the Wilcoxon rank sum test were used for
statistical analysis.
RESULTS
Safety evaluation in normal, healthy adults. Ten volunteers
inhaled rimantadine SPA at a concentration of 40 ,ug/liter of
air for 15 min to 4 h; mean respiratory symptom scores were
significantly higher after rimantadine SPA than after placebo
inhalation (Table 1). Nasal irritation was the only symptom
that occurred significantly more often after rimantadine
inhalation than after placebo inhalation (9 of 10 versus 0 of 10
subjects, respectively, P = 0.0001; Fisher two-tailed exact
test). The irritation increased in severity with increasing
duration of inhalation, with three of four volunteers in the
4-h group reporting severe irritation. One volunteer ceased
aerosol exposure after 50 min because of nasal irritation.
When PBS was used as a diluent at the same rimantadine
aerosol concentration (40 pug/liter of air), the mean respira-
tory symptom scores remained higher compared with the
scores obtained with placebo (Table 1). Nasal irritation was
still a prominent complaint, with three of four volunteers
experiencing nasal irritation.
With the delivery of aerosol at a concentration of 20
pug/liter of air, the SPA inhalations were well tolerated (Table
1). Of the 13 volunteers who received SPA exposures with
durations of 4 to 12 h, only two noted mild irritation during
rimantadine SPA inhalation, whereas one subject noted mild
irritation during sterile water (placebo) SPA inhalation.
There were no changes in mean FEV1, FVC, FEV1/FVC,
FEF25-75, diffusing capacity of carbon monoxide, or airways
resistance following rimantadine or placebo SPA inhalation
(Table 2). One volunteer had a significant decrease in FEV1
after both rimantadine and placebo SPA inhalation; how-
ever, the volunteer had no subjective complaints, and no
wheezing was noted on auscultation of the lungs.
Safety evaluation in adults with acute influenza. Three-day
SPA inhalations of rimantadine from a reservoir concentra-
tion of 2 mg/ml were well tolerated by the nine volunteers
with acute influenza. There was more nasal irritation in the
rimantadine treated group than in the placebo group (6 of 9
versus 0 of 9 subjects, respectively; P = 0.009, Fisher
two-tailed exact test). However, the irritation was mild and
short-lived (duration of less than 15 min); no volunteer
discontinued aerosol treatment.
Six volunteers with proven influenza A virus infection
received rimantadine SPA and seven volunteers received
placebo. The treated group had significantly lower influenza
virus titers 24 h after the study was begun and significantly
fewer positive cultures, but carry-over of rimantadine in
secretions as an explanation for the reductions could not be
excluded. Duration of fever was shorter in the treated group,
but the reduction was not significant. No significant differ-
ences in complete blood counts or chemistries occurred
among the treated volunteers compared with those among
the volunteers given placebo.
Pharmacokinetic data. Pharmacokinetic parameters for
each of the normal, healthy subjects are presented in Table
3. The mean rimantadine half-life was 24.1 + 10.9 h for the
SPA dose and 25.2 + 3.7 h for the oral dose. The bioavail-
ability of the aerosol dose of rimantadine compared with oral
administration was 45.6 ± 10.6% for the five subjects stud-
ied. Individual bioavailabilities ranged from 36.7 to 60.8%. If
it is assumed that the oral bioavailability of rimantadine is
close to 1 (19), then pharmacokinetic parameters of total
clearance and volume of distribution can be calculated from
these data and are given in Table 3. Similar data for the
aerosol dose were obtained by correcting the parameters for
the fraction of rimantadine reaching the systemic circulation
by the aerosol route of administration (bioavailability).
Rimantadine levels in plasma were significantly higher
after oral compared with those after SPA administration at
each of the time points that levels were measured (Fig. 1),
and mean peak levels in serum were 8.6-fold higher after oral
administration (255.0 ± 30.0 versus 29.7 ± 10.8 ng/ml,
respectively). Levels of rimantadine in nasal washings at 12
h were almost 100-fold higher after SPA than after oral
administration (6,650 ± 2,860 and 66.6 ± 20.4 ng/ml, respec-
tively); rimantadine was still present in nasal secretions 12 h
after completion of SPA inhalation in the three volunteers
tested (259 + 45 ng/ml). The percentage of rimantadine
excreted unchanged in the urine in the first 24 h was <1% in
both groups.
The rimantadine levels in plasma were consistently, but
not significantly, higher during the first 12 h of aerosol
administration in the volunteers with an acute febrile upper
respiratory illness compared with those in the normal vol-
unteers (Fig. 1). Levels of drug in plasma were significantly
higher at the end of the third 12-h SPA treatment compared
with those at the end of the first 12-h treatment (88.3 ± 44.4
versus 47.9 ± 23.7 ng/ml, respectively; P < 0.01), but they
were still one-third of the peak levels seen after oral admin-
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.~ .r Environmental sampling. Rimantadine was detected at
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"0 W w s Q sS,very low concentrations in air samples from the rooms of the
first two treated and infected individuals (Table 4). There0o5i°O i t were 15 air changes per hour in these rooms. No rimantadine
,I+ I+ c was detected in the plasma of two investigators who were in
3- 0 O ~ O o °0the patients' rooms for 40 to 160 min/day during the envi-
ronmental sampling.
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LA 0> o 0> : OWe reported on the safety, tolerability, and pharmacoki-
0 ~ n i netics of rimantadine SPA generated from a modified Colli-
son nebulizer in normal volunteers and volunteers with acute
oS-~A r' 8influenzal illness. This method of SPA delivery was chosenM I+l+ I+ because of the well-characterized nature of the aerosol
o 0 ~ o - 3 O generated by this nebulizer, our previous experience with
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. this system in studies with ribavirin, and our goal of evalu-
Az-a~8l >ating rimantadine in combination with ribavirin for SPA0° treatment of influenza A virus infection.
O1+l+I +It E. | | When delivered in a concentration of 40 pg/liter of air for
c8 0. o<ch X up to 4 h, rimantadine SPA was associated with local (nasal)
toxicity in normal volunteers. However, at the lower con-
< LO vN 4. centration of 20 p,g/liter of air, rimantadine SPA was well
1It+ I + tolerated both by normal volunteers for up to 12 h and by
.,~~~ - , volunteers with acute influenza for 36 h of administration
00 -o. over 3 days. Nasal burning or irritation was the most
common side effect associated with rimantadine SPA admin-
- o istration, but at the dose of 20 ,ug/liter of air, it was minimal.
03II + Unpleasant smell or taste, which was reported as a common1+1+ 1+xo Oo £ eside effect in a previous study (22), was uncommon.
I+ 3 CL00 The pharmacokinetics of an oral dose of 200 mg of
rimantadine were similar to those previously reported by
0. 00
s s s Hayden et al. (19). The half-life, clearance, and volume of
0. 1+1+It It Itdistribution of rimantadine reported by those investigators00oo j x were in good, agreement with similar parameters obtained
from the present investigation. For example, parameters
0;<.8o from the previous work (19) for half-life, clearance, and
_0oxoxo\volume of distribution were 36.5 h, 20.4 liter/h, and 986It I+ 2 liters, respectively, compared with our values of 25.2 h, 25.3
I.." I-A oliters/h, and 904 liters, respectively. Following SPA admin-
.T2 istration of rimantadine, only 45.6% of the dose reached the
m4 I-A xsystemic circulation, and mean peak levels in serum were
>ot4os 8.6-fold lower. Whether this was due to a lower fraction of
1+1+It I It dose available for absorption or to first-pass lung metabolism
8 0o o requires further study, but the lower levels in serum are
potentially important since central nervous system and gas-
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TABLE 3. Rimantadine pharmacokinetic data following oral or SPA administrationa
Oralb SPA"
Subject no. AUC 4/2 CL V AUC 4/2 CL V FSPA/Oral
(ng h/ml) (h) (liters/h) (liters) (ng h/ml) (h) (liters/h)d (liters)d
1
2
3
4
5
7,559
5,929
8,091
10,462
8,924
19.6
23.4
27.7
28.8
26.5
26.5
33.7
24.7
19.1
22.4
747
1,136
987
794
857
1,436
690
1,393
1,915
607
18.6
18.1
26.1
42.3
15.3
27.9
43.5
26.3
13.0
38.9
750
1,135
989
794
860
0.608
0.431
0.516
0.357
0.367
Mean ± SD 8,193 + 1,675 25.2 ± 3.7 25.3 ± 5.5 904 ± 158 1,208 ± 551 24.1 ± 10.9 29.9 ± 11.9 906 ± 157 0.456 ± 0.106
a Abbreviations: AUC, area under the curve; t512,3, elimination half-life; CL, total plasma clearance; V, volume of distribution; FSPA/Oral, drug bioavailabilityfor SPA versus oral administration.
b Oral dose was 200 mg.
c The mean estimated SPA dose was 68 mg (range, 64 to 71 mg).
d Corrected for drug bioavailability for SPA versus oral administration.
trointestinal side effects have been correlated with peak
levels in serum (18). The mean concentration in nasal wash
specimens after 12 h of treatment was 6,650 ng/ml. The 50%
inhibitory concentration of rimantadine against several influ-
enza A viruses by the plaque reduction assay has previously
been reported to be 200 to 400 nglml (16), a concentration
which was less than 10% that achieved in the nasal wash
specimens after SPA delivery.
Exposure of health care workers to drug delivered by the
aerosol route is a potential concern. Ribavirin has been
reported to be present in the environment when adminis-
tered by SPA to infants with respiratory syncytial virus
infections (7). In addition, drug was detected in one speci-
men from a health care worker who was exposed to the
aerosol (7). In our study, rimantadine was also found in the
environment. However, it was not detected in multiple
plasma specimens from the two investigators from whom
samples were obtained. The number of room air changes per
hour was higher than the minimum number (two) recom-
mended for patient rooms (1), and drug levels in room air
may be higher under other conditions. The importance of
this level of drug exposure to health care workers remains to
be determined in future studies.
Resistance to rimantadine after oral administration has
been reported in several recent studies (4, 15, 29). The
emergence of rimantadine resistance was not examined in
this study. Although the clinical significance of rimantadine
resistance remains to be determined, it is possible that the
use of combination therapy (rimantadine plus ribavirin) may
prevent resistance from emerging since strains that are
resistant to ribavirin have not been reported (32).
Rimantadine SPA at a concentration of 20 ,ug/liter of air
appears to be safe and well tolerated by both healthy
TABLE 4. Rimantadine levels in room air'
Rimantadine concn(ng/liter of air [mean ± SD])
ob <2
0.25c 7.0 ± 0.2
2 12.2 ± 4.9
4 16.8 ± 6.4
8 15.0 ± 10.1
12 17.0 ± 8.3
a Paired 5-min collections were made by using all glass impingers in two
different rooms on each of 3 consecutive days of treatment.
b Collections were made on second and third days.
c Collections were made on the first day only.
volunteers and those with acute influenza. These studies
suggest that an aerosol concentration of 20 ,ug/liter of air is
near the maximal tolerable dose. The pharmacokinetics
suggest that a lower reservoir concentration of rimantadine
could be used to achieve levels in the mucosa greater than
the 50% inhibitory concentration of most influenza A vi-
ruses; the mild local toxicity could then be decreased even
further.
Because of its efficacy in animal models of pneumonia
caused by influenza virus, rimantadine SPA deserves further
evaluation for its efficacy in the treatment of naturally
acquired influenza A virus infections in humans. Further-
more, evaluation of SPA delivery of the combination of
rimantadine and ribavirin in humans should be considered.
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